← Eichor
Study identifier: NCT05198154 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

Condition: Advanced Lung Non-Small Cell Carcinoma  ·  Sponsor: Fang Wu

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)

This description comes directly from the study's public registry record.

Talk to the study team

Chunhong Hu, professor  ·  +86 13508486908  ·  huchunh5829@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Oncology Department，Second Xiangya Hospital of Central South UniversityChangsha, Hunan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05198154